These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 25384486)

  • 1. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A; Ekelund M; Fletcher MA; Nyman L
    PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.
    Li ST; Tancredi DJ
    Pediatrics; 2010 Jan; 125(1):26-33. PubMed ID: 19948570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.
    Wiese AD; Griffin MR; Zhu Y; Mitchel EF; Grijalva CG
    Vaccine; 2016 Dec; 34(50):6243-6249. PubMed ID: 27832918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
    Tsakir C; Özdemir H; Arga G; Konca HK; Çakmak Taşkın E; Öcal D; Çiftçi E; İnce E
    Mikrobiyol Bul; 2022 Jul; 56(3):466-479. PubMed ID: 35960238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.
    Simonsen L; Taylor RJ; Schuck-Paim C; Lustig R; Haber M; Klugman KP
    Lancet Respir Med; 2014 May; 2(5):387-94. PubMed ID: 24815804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England.
    Saxena S; Atchison C; Cecil E; Sharland M; Koshy E; Bottle A
    J Infect; 2015 Oct; 71(4):428-36. PubMed ID: 26159503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pneumococcal conjugate vaccine had a sustained effect on Swedish children 8 years after its introduction.
    Alfvén T; Bennet R; Granath A; Dennison SH; Eriksson M
    Acta Paediatr; 2024 Apr; 113(4):764-770. PubMed ID: 38217260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Yanai T; Yoshida S; Takeuchi M; Kawakami K
    Vaccine; 2023 Jun; 41(29):4313-4318. PubMed ID: 37286407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.
    Poehling KA; Talbot TR; Griffin MR; Craig AS; Whitney CG; Zell E; Lexau CA; Thomas AR; Harrison LH; Reingold AL; Hadler JL; Farley MM; Anderson BJ; Schaffner W
    JAMA; 2006 Apr; 295(14):1668-74. PubMed ID: 16609088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.
    Mackenzie GA; Hill PC; Sahito SM; Jeffries DJ; Hossain I; Bottomley C; Uchendu U; Ameh D; Ndiaye M; Osuorah CD; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Ahameefula E; Muhammad BS; Fombah AE; Saha D; Mackenzie R; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Sowe D; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
    Lancet Infect Dis; 2017 Sep; 17(9):965-973. PubMed ID: 28601421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
    Martinelli D; Pedalino B; Cappelli MG; Caputi G; Sallustio A; Fortunato F; Tafuri S; Cozza V; Germinario C; Chironna M; Prato R;
    Hum Vaccin Immunother; 2014; 10(1):33-9. PubMed ID: 24096297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; Elberse KE; de Melker HE; van der Ende A; Knol MJ
    Vaccine; 2016 Feb; 34(8):1077-85. PubMed ID: 26778420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.